Aspenbio Pharma (APPY) 2.23 $APPY
Pre-Market Scans on Top Gainers -- Research on Athlon Energy, Venaxis, Desarrolladora Homex, and ImmunoGen
PR Newswire - Thu Apr 10, 12:30PM CDT
On Wednesday, April 09, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,183.90, up 1.72%, the Dow Jones Industrial Average ended the session at 16,437.18, up 1.11%, and the S&P 500 edged 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Athlon Energy Inc. (NYSE: ATHL), Venaxis Inc. (NASDAQ: APPY), Desarrolladora Homex S.A.B. de C.V. (NYSE: HXM) and ImmunoGen Inc. (NASDAQ: IMGN). Free technical research on ATHL, APPY, HXM and IMGN can be downloaded upon signing up at:
Venaxis, Inc. Closes Public Offering of Common Shares
PR Newswire - Tue Apr 08, 3:01PM CDT
Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any.
Nasdaq stocks posting largest volume increases
AP - Thu Apr 03, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Venaxis (APPY) Stock Is Down Today
at The Street - Thu Apr 03, 10:25AM CDT
Venaxis (APPY) fell on Thursday after the diagnostic company announced the pricing of its public offering of common stock. Venaxis is offering 8,335,000 shares at $2.40 a share for a total of $20 million. The offering includes a 30-day option for...
Stock to Watch: AspenBio Pharma Down 11.1% (APPY)
Comtex SmarTrend(R) - Thu Apr 03, 10:11AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.1% to $2.41 on 2.6x average daily volume. Thus far today, AspenBio Pharma has traded 2.0 million shares, vs. average volume of 759,000 shares per day. The stock has underperformed the Dow (-11.1% to the Dow's -0.1%) and underperformed the S&P 500 (-11.1% to the S&P's -0.1%) during today's trading.
Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares
PR Newswire - Thu Apr 03, 8:00AM CDT
Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the pricing of an underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about April 8, 2014, subject to customary closing conditions.
Venaxis, Inc. Announces Proposed Public Offering of Common Shares
PR Newswire - Wed Apr 02, 3:01PM CDT
Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Venaxis Files for FDA Clearance of APPY1 Test
PR Newswire - Mon Mar 31, 6:30AM CDT
CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis(TM) has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AspenBio Pharma Up 27.2%, Shares Break Through Resistance (APPY)
Comtex SmarTrend(R) - Thu Mar 13, 10:16AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 27.2% to $3.45 on 17.9x average daily volume. AspenBio Pharma has traded 6.8 million shares thus far today, vs. average volume of 378,000 shares per day. The stock has outperformed the Dow (27.2% to the Dow's -0.2%) and outperformed the S&P 500 (27.2% to the S&P's -0.2%) during today's trading.
Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Thu Mar 13, 6:00AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study. The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks.
Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Wed Mar 12, 4:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
Investors look to Lighten Up on Shares of AspenBio Pharma, Shares Down 11.6% (APPY)
Comtex SmarTrend(R) - Mon Jan 27, 11:41AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.6% to $2.20 on 1.6x average daily volume. AspenBio Pharma has traded 835,000 shares thus far today, vs. average volume of 538,000 shares per day. The stock has underperformed the Dow (-11.6% to the Dow's -0.4%) and underperformed the S&P 500 (-11.6% to the S&P's -0.8%) during today's trading.
Venaxis Inc concludes milestone patient enrollment in pivotal clinical trial of APPY1 Test
M2 - Mon Jan 27, 5:59AM CST
In vitro diagnostic company Inc (Nasdaq:APPY) revealed on Friday the completion of patient enrollment in the US under its pivotal clinical study of the APPY1 Test.
Hot Stock: AspenBio Pharma, Shares Drop 6.3% (APPY)
Comtex SmarTrend(R) - Fri Jan 24, 10:11AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 6.3% to $2.53 on 1.6x average daily volume. Thus far today, AspenBio Pharma has traded 861,000 shares, vs. average volume of 540,000 shares per day. The stock has underperformed the Dow (-6.3% to the Dow's -1.0%) and underperformed the S&P 500 (-6.3% to the S&P's -1.1%) during today's trading.
Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
Pre-Market Scans on Top Gainers -- Research on Athlon Energy, Venaxis, Desarrolladora Homex, and ImmunoGen
PR Newswire - Thu Apr 10, 12:30PM CDT
On Wednesday, April 09, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,183.90, up 1.72%, the Dow Jones Industrial Average ended the session at 16,437.18, up 1.11%, and the S&P 500 edged 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Athlon Energy Inc. (NYSE: ATHL), Venaxis Inc. (NASDAQ: APPY), Desarrolladora Homex S.A.B. de C.V. (NYSE: HXM) and ImmunoGen Inc. (NASDAQ: IMGN). Free technical research on ATHL, APPY, HXM and IMGN can be downloaded upon signing up at:
Venaxis, Inc. Closes Public Offering of Common Shares
PR Newswire - Tue Apr 08, 3:01PM CDT
Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any.
Nasdaq stocks posting largest volume increases
AP - Thu Apr 03, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Venaxis (APPY) Stock Is Down Today
at The Street - Thu Apr 03, 10:25AM CDT
Venaxis (APPY) fell on Thursday after the diagnostic company announced the pricing of its public offering of common stock. Venaxis is offering 8,335,000 shares at $2.40 a share for a total of $20 million. The offering includes a 30-day option for...
Stock to Watch: AspenBio Pharma Down 11.1% (APPY)
Comtex SmarTrend(R) - Thu Apr 03, 10:11AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.1% to $2.41 on 2.6x average daily volume. Thus far today, AspenBio Pharma has traded 2.0 million shares, vs. average volume of 759,000 shares per day. The stock has underperformed the Dow (-11.1% to the Dow's -0.1%) and underperformed the S&P 500 (-11.1% to the S&P's -0.1%) during today's trading.
Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares
PR Newswire - Thu Apr 03, 8:00AM CDT
Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the pricing of an underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about April 8, 2014, subject to customary closing conditions.
Venaxis, Inc. Announces Proposed Public Offering of Common Shares
PR Newswire - Wed Apr 02, 3:01PM CDT
Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Venaxis Files for FDA Clearance of APPY1 Test
PR Newswire - Mon Mar 31, 6:30AM CDT
CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis(TM) has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AspenBio Pharma Up 27.2%, Shares Break Through Resistance (APPY)
Comtex SmarTrend(R) - Thu Mar 13, 10:16AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 27.2% to $3.45 on 17.9x average daily volume. AspenBio Pharma has traded 6.8 million shares thus far today, vs. average volume of 378,000 shares per day. The stock has outperformed the Dow (27.2% to the Dow's -0.2%) and outperformed the S&P 500 (27.2% to the S&P's -0.2%) during today's trading.
Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Thu Mar 13, 6:00AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study. The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks.
Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Wed Mar 12, 4:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
Investors look to Lighten Up on Shares of AspenBio Pharma, Shares Down 11.6% (APPY)
Comtex SmarTrend(R) - Mon Jan 27, 11:41AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.6% to $2.20 on 1.6x average daily volume. AspenBio Pharma has traded 835,000 shares thus far today, vs. average volume of 538,000 shares per day. The stock has underperformed the Dow (-11.6% to the Dow's -0.4%) and underperformed the S&P 500 (-11.6% to the S&P's -0.8%) during today's trading.
Venaxis Inc concludes milestone patient enrollment in pivotal clinical trial of APPY1 Test
M2 - Mon Jan 27, 5:59AM CST
In vitro diagnostic company Inc (Nasdaq:APPY) revealed on Friday the completion of patient enrollment in the US under its pivotal clinical study of the APPY1 Test.
Hot Stock: AspenBio Pharma, Shares Drop 6.3% (APPY)
Comtex SmarTrend(R) - Fri Jan 24, 10:11AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 6.3% to $2.53 on 1.6x average daily volume. Thus far today, AspenBio Pharma has traded 861,000 shares, vs. average volume of 540,000 shares per day. The stock has underperformed the Dow (-6.3% to the Dow's -1.0%) and underperformed the S&P 500 (-6.3% to the S&P's -1.1%) during today's trading.
Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
